← Back to patent-cliff list
ST-617
Tier C — Watch / tradeST-617
Supportive Therapeutics LLC
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Updating
Indications (approved)：Stomatitis, Head and neck cancer
Regional status
US
Phase I
2020-05-04
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of ST-617?
Approved indications include: Stomatitis, Head and neck cancer.
When does the ST-617 patent expire?
No public expiry year is available for ST-617 yet; this page updates once verified.
How do I get a quote for ST-617 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-07